GHK-Cu peptide research examines a small copper-binding molecule and its biological activity. The compound is often described as a copper peptide, but that familiar name does not establish that every product containing it has the same effects.

What is the GHK-Cu copper tripeptide?

GHK refers to glycine, histidine and lysine, a sequence of three amino acids. The copper complex has been investigated in tissue-related research. Maquart and colleagues described GHK's affinity for copper and reported work on collagen synthesis in fibroblast cultures in 1988.

What the collagen study can tell us

The researchers observed an effect in cultured fibroblasts, cells involved in connective tissue. This supports a laboratory research finding under those experimental conditions. It does not demonstrate a cosmetic result, wound-healing treatment or hair-growth effect for every GHK-Cu preparation.

To assess a later claim, ask whether it concerns the same material, a comparable formulation and a relevant outcome. A laboratory measurement of collagen synthesis is not interchangeable with visible changes in a person's skin.

Topical and injectable products need separate evidence

GHK-Cu serum, topical and injection searches refer to different uses. Evidence cannot simply be carried across those routes. The FDA's compounding information notes limited human safety data for injectable GHK-Cu; a naturally occurring ingredient should not be assumed safe to inject.

Read the current ingredient list

The Svelta Glow Pen listing names GHK-Cu as part of a blend with BPC-157 and TB-500. That is a catalogue statement about ingredients, not proof that the finished blend reproduces a published GHK-Cu result.

Use the GHK-Cu library profile for terminology, and the GHK-Cu and KPV guide for a comparison of research contexts.

Sources: Maquart et al., FEBS Letters 238(2), 343–346 (1988), DOI 10.1016/0014-5793(88)80509-X; FDA compounding safety information. Further education is available at Svelta Labs. This is not a recommendation to use a research product for treatment.

Sources

Maquart et al., GHK-Cu primary study: https://pubmed.ncbi.nlm.nih.gov/3169264/
FDA compounding safety information: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks